Reboxetine: A selective norepinephrine reuptake inhibitor for the treatment of depression

Annals of Pharmacotherapy

Volumn 34, Issue 11, 2000, Pages 1302-1312

  Scates, Ann C ^a   Doraiswamy, P Murali ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Depression; Reboxetine

Indexed keywords

NORADRENALIN UPTAKE INHIBITOR; REBOXETINE;

CONSTIPATION; DEPRESSION; DRUG EFFICACY; DRUG TOLERANCE; HUMAN; INSOMNIA; PRIORITY JOURNAL; RATING SCALE; REVIEW; SWEATING; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; ANTIDEPRESSIVE AGENTS; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS; DEPRESSIVE DISORDER; DRUG INTERACTIONS; HALF-LIFE; HUMANS; MIDDLE AGED; MORPHOLINES; TISSUE DISTRIBUTION;

EID: 0033766270     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19335     Document Type: Review

References (45)

1. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States
2. The economic burden of depression in 1990
3. The catecholamine hypothesis of affective disorders: A review of supporting evidence
4. The indoleamine hypothesis of depression: An overview and pilot study
5. The role of corticotropin-releasing factor in depression and anxiety disorders
6. Effects of antidepressant drugs on different receptors in the brain
7. Antidepressant adverse drug reactions
8. Major depression: Assessing the role of new antidepressants
9. Rationale for the development of noradrenaline reuptake inhibitors
10. Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: Most antidepressants selectively block norepinephrine uptake
11. The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor
12. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor
13. Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics
14. Is there a role of a pure noradrenergic drug in the treatment of depression
15. Pharmacokinetics of antidepressants: Why and how they are relevant to treatment
16. Pharmacokinetics of reboxetine in healthy volunteers. Single against repeated oral doses and lack of enzymatic alterations
17. Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding
18. Comparison of the disposition and of the metabolic pattern of reboxetine, a new antidepressant, in the rat, dog, monkey and man
19. Pharmacokinetics of single-dose reboxetine in volunteers with renal insufficiency
20. Long-term treatment of depression
21. Clinical efficacy of reboxetine: A comparative study with desipramine, with methodological considerations
22. Efficacy and tolerability of reboxetine compared with imipramine in a double blind study in patients suffering from major depressive episodes
23. Reboxetine versus fluoxetine: An overview of efficacy and tolerability
24. Reboxetine: A double-blind comparison with fluoxetine in major depressive disorder
25. Double-blind, placebo-controlled, study with reboxetine in patients with severe major depressive disorder
26. Development and validation of a social functioning scale, the Social Adaptation Self-Evaluation Scale
27. Continuation therapy for major depressive episodes: How long should it be maintained
28. Reboxetine, a unique NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder
29. Reboxetine in the maintenance therapy of depressive disorder in the elderly: A long-term open study
30. Maintenance phase efficacy of sertraline for chronic depression: A randomized controlled trial
31. Predictors of relapse during fluoxetine continuation of maintenance treatment of major depression
32. The effects of reboxetine and amitriptyline, with and without alcohol, on cognitive function and psychomotor performance
33. Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans
34. Evaluation of the potential pharmaokinetic/pharmacodynamic interaction between fluoxetine and reboxetine in healthy volunteers